$4.01
5.67% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US6406714005
Symbol
NEPH

Nephros Inc Stock price

$4.01
+1.94 93.63% 1M
+2.46 158.71% 6M
+2.54 172.79% YTD
+1.84 84.79% 1Y
-3.97 49.75% 5Y
-2.11 34.48% 10Y
-0.03 0.74% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.22 5.67%
ISIN
US6406714005
Symbol
NEPH
Sector

Key metrics

Market capitalization $42.51m
Enterprise Value $38.45m
P/E (TTM) P/E ratio 57.29
EV/FCF (TTM) EV/FCF 76.89
EV/Sales (TTM) EV/Sales 2.48
P/S ratio (TTM) P/S ratio 2.74
P/B ratio (TTM) P/B ratio 4.58
Revenue growth (TTM) Revenue growth 10.31%
Revenue (TTM) Revenue $15.52m
EBIT (operating result TTM) EBIT $772.00k
Free Cash Flow (TTM) Free Cash Flow $500.00k
Cash position $4.08m
EPS (TTM) EPS $0.07
P/E forward negative
P/S forward 2.62
EV/Sales forward 2.37
Short interest 0.05%
Show more

Is Nephros Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Nephros Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Nephros Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Nephros Inc forecast:

Buy
100%

Financial data from Nephros Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
16 16
10% 10%
100%
- Direct Costs 5.83 5.83
4% 4%
38%
9.69 9.69
14% 14%
62%
- Selling and Administrative Expenses 7.76 7.76
13% 13%
50%
- Research and Development Expense 0.99 0.99
16% 16%
6%
0.95 0.95
177% 177%
6%
- Depreciation and Amortization 0.17 0.17
32% 32%
1%
EBIT (Operating Income) EBIT 0.77 0.77
152% 152%
5%
Net Profit 0.80 0.80
156% 156%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Nephros Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Head office United States
CEO Robert Banks
Employees 31
Founded 1997
Website www.nephros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today